Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) is now available.
China Resources Pharmaceutical Group Ltd. has announced a Cooperation Agreement between its indirect subsidiary, CR Sanjiu, and CR Power to collaborate on new energy projects. This agreement, effective from May 14, 2025, to December 31, 2027, focuses on dual-use photovoltaic power projects and other new energy initiatives. The partnership is part of connected transactions under the Listing Rules, exempt from independent shareholders’ approval but subject to reporting and review requirements. This collaboration signifies a strategic move to enhance the company’s involvement in sustainable energy solutions, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
Average Trading Volume: 13,813,754
Technical Sentiment Signal: Sell
Current Market Cap: HK$31.48B
Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.